The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.
 
James M. Cleary
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Merck; Tesaro
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Roche
 
Gopa Iyer
Consulting or Advisory Role - Bayer; Janssen; Mirati Therapeutics
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Do-Youn Oh
Consulting or Advisory Role - AstraZeneca/MedImmune; Merck Serono
Research Funding - AstraZeneca/MedImmune
 
Ingo K. Mellinghoff
Honoraria - Roche
Consulting or Advisory Role - Agios; Black Diamond Therapeutics; Debiopharm Group; Puma Biotechnology; Voyager Therapeutics
Research Funding - Amgen; General Electric; Lilly
Travel, Accommodations, Expenses - Agios; AstraZeneca; Puma Biotechnology; Roche; Voyager Therapeutics
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; H3 Biomedicine; Klus Pharma; QED Therapeutics; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Travel, Accommodations, Expenses - Debiopharm Group; Taiho Pharmaceutical
 
Matthew C.H. Ng
Honoraria - ASLAN Pharmaceuticals; Lilly; MSD Oncology; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; MSD Oncology
Speakers' Bureau - Lilly
Research Funding - ASLAN Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; Taiho Pharmaceutical
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Aduro Biotech; Clearlight Diagnostics; DarwinHealth; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; IBM; Immunomedics; Inflection Biosciences; Mersana; Origimed; PACT Pharma; Pieris Pharmaceuticals; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Xencor
Speakers' Bureau - Chugai Pharma
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Seagen; Taiho Pharmaceutical
 
Ignacio Matos
No Relationships to Disclose
 
Tsu-Yi Chao
No Relationships to Disclose
 
Rafik Ait Sarkouh
Employment - Debiopharm Group
 
Kira Cretegny
Employment - Debiopharm Group
 
Valerie Nicolas-Metral
Employment - Debiopharm Group
 
Anna Pokorska-Bocci
Employment - Debiopharm Group
 
Anne Vaslin
Employment - Debiopharm Group
 
Claudio Zanna
Employment - Debiopharm Group
 
Angela Zubel
Employment - Debiopharm Group
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences
 
Keith Flaherty
Stock and Other Ownership Interests - Apricity Health; Checkmate Pharmaceuticals; Clovis Oncology; FOGPharma; Fount Therapeutics; Kinnate Biopharma; Loxo; Oncoceutics; PIC Therapeutics; Shattuck Labs; Strata Oncology; Tvardi Therapeutics; X4 Pharma
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Array BioPharma; Asana Biosciences; Boston Biomedical; Bristol-Myers Squibb; Cell Medica; Debiopharm Group; FOGPharma; Genentech; Incyte; Lilly; Loxo; Merck; Neon Therapeutics; Novartis; Oncoceutics; Pierre Fabre; Roche; Sanofi; Shattuck Labs; Takeda; Tolero Pharmaceuticals; Tvardi Therapeutics; Verastem
Research Funding - Novartis; Sanofi
Travel, Accommodations, Expenses - Debiopharm Group; Pierre Fabre
 
David Michael Hyman
Employment - Lilly; Loxo
Stock and Other Ownership Interests - Fount Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Fount Therapeutics; Genentech; Lilly; Pfizer
Research Funding - AstraZeneca; Bayer; Loxo; Puma Biotechnology
Travel, Accommodations, Expenses - Chugai Pharma; Genentech